Ponesimod

• CAT Number: I005128
• CAS Number: 854107-55-4
• Molecular Formula: C23H25ClN2O4S
• Molecular Weight: 460.97
• Purity: 98%
• Synonyms: (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
• Target: S1P receptor
• Target Protein: P21453
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: S1PR1：6 nM (IC50)
• InChI: InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
• InChIKey: LPAUOXUZGSBGDU-ULCCENQXSA-N
• SMILES: CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C

Ponesimod（Cat No.:I005128）is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator used to treat relapsing forms of multiple sclerosis (MS). By binding to S1P1 receptors, it prevents lymphocytes from exiting lymph nodes, thereby reducing the number of circulating immune cells that can attack the central nervous system. This mechanism helps to lower the frequency of MS relapses and slow disease progression. Ponesimod offers a targeted approach with fewer cardiovascular side effects compared to earlier S1P modulators, making it a valuable option in managing MS.

Reference

[1]. Bolli MH, et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem. 2010 May 27;53(10):4198-211.
[Content Brief]

[2]. Piali L, et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther. 2011 May;337(2):547-56.
[Content Brief]

[3]. Brossard P, et al. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol. 2013 Dec;76(6):888-96.
[Content Brief]